ClinicalTrials.gov record
Not listed Phase 1 Interventional

Busulfan, Melphalan, and Antithymocyte Globulin Followed By Umbilical Cord Blood Transplant in Treating Young Patients With Refractory or Relapsed Malignant Solid Tumors

ClinicalTrials.gov ID: NCT00436761

Public ClinicalTrials.gov record NCT00436761. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 2:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I Study to Examine the Toxicity of Killer IG-Like Receptor (KIR) Mismatched Umbilical Cord Blood for Pediatric Patients With Malignant Solid Tumors

Study identification

NCT ID
NCT00436761
Recruitment status
Not listed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Milton S. Hershey Medical Center
Other
Enrollment
20 participants

Conditions and interventions

Interventions

  • allogeneic hematopoietic stem cell transplantation Procedure
  • anti-thymocyte globulin Biological
  • busulfan Drug
  • cyclosporine Drug
  • flow cytometry Other
  • graft-versus-tumor induction therapy Biological
  • immunologic technique Other
  • laboratory biomarker analysis Other
  • melphalan Drug
  • methylprednisolone Drug
  • sargramostim Biological
  • umbilical cord blood transplantation Procedure

Procedure · Biological · Drug + 1 more

Eligibility (public fields only)

Age range
Up to 21 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2004
Primary completion
Not listed
Completion
Not listed
Last update posted
Dec 17, 2013

Started 2004

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Penn State Cancer Institute at Milton S. Hershey Medical Center Hershey Pennsylvania 17033-0850

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00436761, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 17, 2013 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00436761 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →